Madrigal Pharmaceuticals (MDGL) Total Debt Growth (1y) (2011 - 2026)
Powered by 
Analysis
Madrigal Pharmaceuticals (MDGL) Total Debt Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 0.10% |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 12.42% |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | 3.78% |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 0.00% |
| 10 | Madrigal Pharmaceuticals | 15.80 Bn | 14.96 Bn | - | 187.89% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 187.89% |
| Mar 31, 2026 | 188.40% |
| Dec 31, 2025 | 189.09% |
| Sep 30, 2025 | 190.17% |
| Jun 30, 2025 | 1.52% |
| Mar 31, 2025 | 1.61% |
| Dec 31, 2024 | 1.81% |
| Sep 30, 2024 | -21.36% |
| Jun 30, 2024 | -11.43% |
| Mar 31, 2024 | 2.15% |
| Dec 31, 2023 | 134.29% |
| Sep 30, 2023 | 119.41% |
| Jun 30, 2023 | 97.31% |
| Jun 30, 2016 | -99.89% |
| Mar 31, 2016 | -80.04% |
| Dec 31, 2015 | 284.94% |
| Sep 30, 2015 | -57.12% |
| Jun 30, 2015 | -49.95% |
| Mar 31, 2015 | -44.56% |
| Dec 31, 2014 | -40.61% |